Amgen Inc. is emphasizing its comprehensive approach to cancer, but the groundwork the firm has laid in immunotherapy might be what helps the franchise move forward.
During a June 1 briefing at the American Society of Clinical Oncology annual meeting in Chicago, Amgen noted that its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?